复方苦参注射液联合EC-T化疗方案治疗乳腺癌术后患者的临床观察  

Clinical Observation of Compound Kushen Injection Combined with EC-T Chemotherapy Regimen in the Treatment of Postoperative Patients with Breast Cancer

作　　者：马志强[1] 李帅[1] 何建鑫 吴海滨[1] 张雅婷 陈梦圆 王文胜[1] MA Zhi-qiang;LI Shuai;HE Jian-xin;WU Hai-bin;ZHANG Ya-ting;CHEN Meng-yuan;WANG Wen-sheng(The First Affiliated Hospital of Henan University,Kaifeng 475000,China)

机构地区：[1]河南大学第一附属医院乳腺甲状腺外科,开封475000

出　　处：《中国合理用药探索》2023年第12期56-60,共5页Chinese Journal of Rational Drug Use

基　　金：国家卫生健康委医院管理研究所乳腺癌单病种诊疗能力提升项目科研课题(RXDBZ-2022-08);2022年度开封市科技发展计划项目(2203028)。

摘　　要：目的:探讨复方苦参注射液联合EC-T化疗方案(即表柔比星联合环磷酰胺化疗后序贯多西他赛方案)对乳腺癌术后患者的肝肾功能、免疫功能及身体功能状态的影响,为临床提供新思路。方法:选取2018年1月~2022年12月的乳腺癌术后患者156例作为研究对象,采用随机数字表法分为对照组和观察组,每组78例。对照组给予EC-T化疗方案,观察组在对照组治疗基础上加用复方苦参注射液。比较治疗前后两组患者肝肾功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、γ-谷氨酰转移酶(GGT)、血尿素氮(BUN)、肌酐(Cr)]、外周血T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+))水平及身体功能状态[卡诺夫斯凯计分(KPS)]。结果:治疗后,两组患者ALT、AST、GGT、BUN、Cr比较均无统计学差异(P>0.05)。治疗后,观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)升高,CD8^(+)降低(P<0.05);对照组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)降低,CD8^(+)升高(P<0.05)。观察组KPS和身体功能状态改善率均优于对照组(P<0.05)。结论:与单用EC-T化疗方案相比,复方苦参注射液联合EC-T化疗方案可改善乳腺癌患者术后化疗期间的免疫功能和身体功能状态,值得临床推广。Objective:To explore the the impact of liver and kidney function,immune function,and quality of life of compound Kushen injection combined with EC-T chemotherapy regimen(docetaxel followed by epirubicin and cyclophosphamide)in the treatment of postoperative patients with breast cancer,and to provide new ideas for clinical practice.Methods:A total of 156 postoperative patients with breast cancer treated during January 2018 to December 2022 were selected and divided into control group and observation group by random number table method,with 78 patients in each group.The control group was treated with EC-T chemotherapy,and the observation group was treated with compound Kushen injection in addition to the control treatment.Liver and kidney function tests[alanine transaminase(ALT),aspartate transaminase(AST),γ-glutamyl transferase(GGT),blood urea nitrogen(BUN),creatinine(Cr)],peripheral blood T cell subsets(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))and physical functional status and Karnofsky performance score(KPS)were compared between the two groups before and after treatment.Results:There was no significant difference in ALT,AST,GGT,BUN and Cr between the two groups(P>0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those before treatment,but the level of CD8^(+)was lower than those before treatment(P<0.05).In the control group,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were decreased and level of CD8^(+)was increased as compare to those before treatment(P<0.05).The KPS and rate of improvement in physical functional status in the observation group were better than those in the control group(P<0.05).Conclusion:Compound Kushen injection combined with EC-T chemotherapy can improve the immune function and physical functional status of breast cancer patients after chemotherapy,which is worthy of clinical promotion.

关 键 词：乳腺癌 中成药 免疫功能 EC-T化疗方案 复方苦参注射液 

分 类 号：R737.9[医药卫生—肿瘤]